Top Reasons BsAbs Not Offered by HCPs in the UK^1,a,b

In the UK, HCPs reported logistical challenges as the top reason for not offering BsAbs to patients

^aTop reason defined as any reason that was given by more than 25% of HCPs during the survey. ^bQuestions about CAR T-cell therapy were not asked to HCPs in UK.

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional.

Reference

Zamagni E, Kevin B, Cormier N, et al. Differences across countries in healthcare provider confidence with CAR-T and bispecific antibody therapies for relapsed/refractory multiple myeloma. Presented at: EHA 2025 Congress; June 12-15, 2025; Milan, Italy. Poster PS1751.

Top Reasons BsAbs Not Offered by HCPs in the UK1,a,b

In the UK, HCPs reported logistical challenges as the top reason for not offering BsAbs to patients

Reference

Top Reasons BsAbs Not Offered by HCPs in the UK^1,a,b